Premixed Lidocaine With Fospropofol Disodium for Safety and Clinical Evaluation Regarding Paresthesia Upon Fospropofol Disodium Injection: A Preclinical Experimental Study and a Randomized Controlled Trial

Abstract

Fospropofol disodium (fospropofol), a water-soluble prodrug of propofol, reduces injection pain and anesthetic requirements but frequently causes paresthesia. Intravenous lidocaine has been shown to alleviate dexamethasone-induced paresthesia, yet its effect on fospropofol-related symptoms remains uncertain. We combined preclinical and clinical studies, first evaluating the safety and pharmacological changes of fospropofol premixed with lidocaine through in vitro and in vivo experiments and then conducting a randomized controlled trial in adult surgical patients to evaluate whether the lidocaine premixing strategy affects the occurrence of fospropofol-induced paresthesia. In the preclinical study, the findings indicated that mixture of fospropofol and lidocaine remained physicochemically stable, with faster onset and longer sedation duration compared with fospropofol alone, without additional adverse effects. In the clinical trial, 74 patients received fospropofol dissolved in either 20 mL of normal saline or 0.75% lidocaine and 72 were included in the primary outcome analysis of paresthesia. This adverse reaction occurred in 83.3% of patients in both groups, mainly within 40–60 s after administration. No group differences were observed in plasma inflammatory markers and phosphate; however, phosphate levels increased postadministration in both groups. This study provides important guidance for clinical practice, showing that premixing lidocaine does not effectively alleviate paresthesia induced by fospropofol.

Keywords

clinical trial / experimental study / fospropofol / lidocaine / paresthesia

References

[1] R. Liu, C. Luo, J. Liu, W. Zhang, Y. Li, and J. Xu, “Efficacy and Safety of FospropofolFD Compared to Propofol When Given During the Induction of General Anaesthesia: A Phase II, Multi-centre, Randomized, Parallel-Group, Active-Controlled, Double-Blind, Double-Dummy Study,” Basic & Clinical Pharmacology & Toxicology 119, no. 1 (2016): 93–100.

[2] C. M. Wu, W. S. Zhang, J. Liu, W. Y. Zhang, and B. W. Ke, “Efficacy and Safety of Fospropofol Disodium for Injection in General Anesthesia Induction for Adult Patients: A Phase 3 Trial,” Frontiers in Pharmacology 12 (2021): 687894.

[3] G. Perron, P. Dolbec, J. Germain, and P. Béchard, “Perineal Pruritus After i.v. dexamethasone Administration,” Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie 50, no. 7 (2003): 749–750.

[4] Y. Zhang, H. Liang, L. Huang, et al., “The Effect of Dilution With Glucose and Prolonged Injection Time on Dexamethasone-induced Perineal Irritation - A Randomized Controlled Trial,” Open Medicine (Warsaw, Poland) 17, no. 1 (2022): 1509–1514.

[5] H. S. Kim, K. R. Cho, J. H. Lee, et al., “Prevention of Pain During Injection of Microemulsion Propofol: Application of Lidocaine Mixture and the Optimal Dose of Lidocaine,” Korean Journal of Anesthesiology 59, no. 5 (2010): 310–313.

[6] H. Borazan, O. Sahin, A. Kececioglu, M. S. Uluer, T. Et, and S. Otelcioglu, “Prevention of Propofol Injection Pain in Children: A Comparison of Pretreatment With Tramadol and Propofol-lidocaine Mixture,” International Journal of Medical Sciences 9, no. 6 (2012): 492–497.

[7] J. Wang, J. Duan, C. Xie, Y. Yu, and Y. Lu, “Comparison Between Intravenous Nalbuphine and Lidocaine in Reducing Propofol-Induced Injection Pain During Gastroscopy: A Randomized Controlled Trial,” Pain and Therapy 9, no. 2 (2020): 563–571.

[8] J. Wang, J. Li, H. Cao, X. Zhou, and Q. Tang, “Intravenous Lidocaine Suppresses Dexamethasone-induced Perineal Pruritus During Anesthesia Induction: A Randomized Controlled, Double Blind Study,” Pakistan Journal of Pharmaceutical Sciences 28, no. 2 (2015): 569–572.

[9] P. Y. Sun, H. G. Li, Q. Y. Xu, et al., “Lidocaine Alleviates Inflammation and Pruritus in Atopic Dermatitis by Blocking Different Population of Sensory Neurons,” British Journal of Pharmacology 180, no. 10 (2023): 1339–1361.

[10] S. M. Fishman, O. A. Caneris, M. P. Stojanovic, and D. Borsook, “Intravenous Lidocaine for Treatment-Resistant Pruritus,” The American Journal of Medicine 102, no. 6 (1997): 584–585.

[11] A. G. Villamil, J. C. Bandi, O. A. Galdame, S. Gerona, and A. C. Gadano, “Efficacy of Lidocaine in the Treatment of Pruritus in Patients With Chronic Cholestatic Liver Diseases,” The American Journal of Medicine 118, no. 10 (2005): 1160–1163.

[12] J. C. McDonald, O. Spruyt, and A. Alhatem, “Control of Intractable Pruritus in a Patient With Cutaneous T-Cell Lymphoma Using a Continuous Subcutaneous Infusion of Lidocaine,” Journal of Pain and Symptom Management 49, no. 4 (2015): e1–3.

[13] R. B. Rhoades, K. N. Leifer, R. Cohan, and H. J. Wittig, “Suppression of Histamine-Induced Pruritus by Three Antihistaminic Drugs,” The Journal of Allergy and Clinical Immunology 55, no. 3 (1975): 180–185.

[14] S. Keshari, A. D. Sipayung, C. C. Hsieh, et al., “IL-6/p-BTK/p-ERK Signaling Mediates Calcium Phosphate-Induced Pruritus,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 33, no. 11 (2019): 12036–12046.

[15] Y. Panahi, S. M. Davoudi, F. Beiraghdar, A. Saadat, and A. Sahebkar, “Relationship Between Levels of IFNγ, TNFα, and TGFβ and Pruritus in Sulfur Mustard-exposed Veterans,” Journal of Immunotoxicology 10, no. 2 (2013): 173–177.

[16] A. Y. Cheng and L. S. Wong, “Uremic Pruritus: From Diagnosis to Treatment,” Diagnostics (Basel, Switzerland) 12, no. 5 (2022): 1108.

[17] W. S. Shim, M. H. Tak, M. H. Lee, et al., “TRPV1 mediates Histamine-induced Itching via the Activation of Phospholipase A2 and 12-lipoxygenase,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 27, no. 9 (2007): 2331–2337.

[18] K. Shimizu, T. Andoh, Y. Yoshihisa, and T. Shimizu, “Histamine Released From Epidermal Keratinocytes Plays a Role in α-Melanocyte-stimulating Hormone-induced Itching in Mice,” The American Journal of Pathology 185, no. 11 (2015): 3003–3010.

[19] S. Jo, E. Y. Gong, W. Yoo, et al., “Anti-Itching and Anti-Inflammatory Effects of Kushenol F via the Inhibition of TSLP Production,” Pharmaceuticals (Basel, Switzerland) 15, no. 11 (2022): 1347.

[20] Y. Shao, Y. Zhu, Z. Xiao, et al., “RNA Sequencing Reveals the Transcriptome Profile of the Atopic Prurigo Nodularis With Severe Itching,” Experimental Dermatology 32, no. 1 (2023): 30–40.

[21] T. Nakamura, N. Yoshida, K. Anzawa, A. Nishibu, and T. Mochizuki, “Itching in a Trichophytin Contact Dermatitis Mouse Model and the Antipruritic Effect of Antifungal Agents,” Clinical and Experimental Dermatology 44, no. 4 (2019): 381–389.

[22] J. D. Blachley, D. M. Blankenship, A. Menter, T. F. Parker, and J. P. Knochel, “Uremic Pruritus: Skin Divalent Ion Content and Response to Ultraviolet Phototherapy,” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 5, no. 5 (1985): 237–241.

[23] S. Keshari, Y. Wang, D. R. Herr, et al., “Skin Cutibacterium Acnes Mediates Fermentation to Suppress the Calcium Phosphate-Induced Itching: A Butyric Acid Derivative With Potential for Uremic Pruritus,” Journal of Clinical Medicine 9, no. 2 (2020): 312.

[24] R. Lengton, E. M. van der Willik, E. N. M. de Rooij, et al., “Effect of Residual Kidney Function and Dialysis Adequacy on Chronic Pruritus in Dialysis Patients,” Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association—European Renal Association 38, no. 6 (2023): 1508–1518.

[25] E. Novak, T. J. Gilbertson, C. E. Seckman, R. D. Stewart, A. R. DiSanto, and S. S. Stubbs, “Anorectal Pruritus After Intravenous Hydrocortisone Sodium Succinate and Sodium Phosphate,” Clinical Pharmacology and Therapeutics 20, no. 1 (1976): 109–112.

[26] D. C. Chien, N. Limjunyawong, C. Cao, et al., “MRGPRX4 mediates Phospho-drug-associated Pruritus in a Humanized Mouse Model,” Science Translational Medicine 16, no. 746 (2024): eadk8198.

[27] J. P. Estebe, “Intravenous Lidocaine,” Best Practice & Research Clinical Anaesthesiology 31, no. 4 (2017): 513–521.

[28] A. Gottschalk, A. M. McKay, Z. M. Malik, M. Forbes, M. E. Durieux, and D. S. Groves, “Systemic Lidocaine Decreases the Bispectral Index in the Presence of Midazolam, but Not Its Absence,” Journal of Clinical Anesthesia 24, no. 2 (2012): 121–125.

[29] D. Y. Qi, K. Wang, H. Zhang, et al., “Efficacy of Intravenous Lidocaine versus Placebo on Attenuating Cardiovascular Response to Laryngoscopy and Tracheal Intubation: A Systematic Review of Randomized Controlled Trials,” Minerva Anestesiologica 79, no. 12 (2013): 1423–1435.

[30] N. Percie du Sert, V. Hurst, A. Ahluwalia, et al., “The ARRIVE Guidelines 2.0: Updated Guidelines for Reporting Animal Research,” PLoS Biology 18, no. 7 (2020): e3000410.

[31] R. J. Brosnan and T. L. Pham, “Carbon Dioxide Negatively Modulates N-methyl-D-aspartate Receptors,” British Journal of Anaesthesia 101, no. 5 (2008): 673–679.

[32] G. F. Rousseau, M. Oram, J. Barrington, M. Priston, and M. Swart, “Plasma Lidocaine Concentrations Following Insertion of 2% Lidocaine Gel Into the Uterine Cavity After Uterine Balloon Thermal Ablation,” British Journal of Anaesthesia 89, no. 6 (2002): 846–848.

[33] W. Li, Y. Zhang, Y. Liu, et al., “In Vitro Kinetic Evaluation of the Free Radical Scavenging Ability of Propofol,” Anesthesiology 116, no. 6 (2012): 1258–1266.

[34] H. Ma, Y. Liu, Z. Li, et al., “Propofol Protects Against Hepatic Ischemia Reperfusion Injury via Inhibiting Bnip3-Mediated Oxidative Stress,” Inflammation 44, no. 4 (2021): 1288–1301.

[35] Y. Zhou, W. Dong, Y. K. Qiu, et al., “Regulating the Activity of GABAergic Neurons in the Ventral Pallidum Alters the General Anesthesia Effect of Propofol,” Neuropharmacology 257 (2024): 110032.

[36] Y. Zhou, J. Yang, J. Liu, Y. Wang, and W. S. Zhang, “Efficacy Comparison of the Novel Water-Soluble Propofol Prodrug HX0969w and Fospropofol in Mice and Rats,” British Journal of Anaesthesia 111, no. 5 (2013): 825–832.

[37] R. Li, W. S. Zhang, J. Liu, M. Tang, Y. Y. Yang, and N. F. Luo, “Minimum Infusion Rates and Recovery Times From Different Durations of Continuous Infusion of Fospropofol, a Prodrug of Propofol, in Rabbits: A Comparison With Propofol Emulsion,” Veterinary Anaesthesia and Analgesia 39, no. 4 (2012): 373–384.

[38] S. Hopewell, A. W. Chan, G. S. Collins, et al., “CONSORT 2025 Statement: Updated Guideline for Reporting Randomised Trials,” BMJ (Clinical Research ed) 389 (2025): e081123.

[39] L. Jalota, V. Kalira, E. George, et al., “Prevention of Pain on Injection of Propofol: Systematic Review and Meta-analysis,” BMJ (Clinical Research Ed) 342 (2011): d1110.

[40] U. Weber, M. Krammel, S. Linke, et al., “Intravenous Lidocaine Increases the Depth of Anaesthesia of Propofol for Skin Incision–a Randomised Controlled Trial,” Acta anaesthesiologica Scandinavica 59, no. 3 (2015): 310–318.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.